© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
September 2019
Impact of Switching Analogue Insulin to Human Insulin in Diabetes
September 27, 2019
Article
Evidence-Based Diabetes Management
Converting from analogue insulin to human insulin is associated with a clinical insignificant increase in glycated hemoglobin of 0.16% but with improved insulin adherence.
Examining the Reality of What Insulin Costs Do to Patients
September 27, 2019
Article
Evidence-Based Diabetes Management
The editor-in-chief of Evidence-Based Diabetes Management™ introduces the special issue, Perspectives on Insulin Pricing, and shares that he has seen rationing among his own patients.
Biosimilar Insulin Could Offer Patients Cost-Saving Options
September 27, 2019
Article
Evidence-Based Diabetes Management
From the Center for Biosimilars®, a discussion on giving patients new, less expensive alternatives for managing diabetes.
How Prepared Is the United States for the Transition of Insulins to Regulation as Biologics?
September 27, 2019
Article
Evidence-Based Diabetes Management
From The Center for Biosimilars®, a discussion of a regulatory change coming in 2020: Insulins have always been biologics from a scientific perspective, and the products themselves will not change as a result of bringing them under regulation as biologics as a matter of law. However, labeling for these products will change.
Could Aiming Insulin at the Liver Be an Answer to Using Less?
September 26, 2019
Article
Evidence-Based Diabetes Management
A new concept for targeting insulin toward the liver could lead to people with diabetes needing less of it to control glycated hemoglobin (A1C) and avoid hypoglycemia.
Gathering Evidence on Insulin Rationing: Answers and Future Questions
September 26, 2019
Article
Evidence-Based Diabetes Management
The results of a study published last year from authors at Yale Diabetes Center suggest that rationing is more common than the healthcare system wants to admit. Senior author Kasia Lipska, MD, MHS, says the findings raise a whole new set of questions.
JDRF's Kowalski Sees Hope in Bipartisan Support for Insulin Pricing Reform
September 26, 2019
Article
Evidence-Based Diabetes Management
Aaron Kowalski, PhD, the new CEO of the JDRF, says in a discussion about insulin pricing that action is needed not only by Congress, but also by insulin makers, health plans, and the executive branch. The most important goal: ending a crosspayment scheme that many blame for potentially deadly price increases.
As a Child, Diabetes Was Hard to Accept. Now She's Living With the Complications
September 25, 2019
Article
Evidence-Based Diabetes Management
The diagnosis of diabetes can be hard for a teenager to accept. Add insulin affordability to the mix, and by the time a young adult learns to live with the disease, the complications have already arrived.
For Young Adults With Type 1 Diabetes, Insulin Costs Can Mean Chasing Benefits, Not Dreams
September 25, 2019
Article
Evidence-Based Diabetes Management
“Diabetes fully ripped my life and potential away. I always grew up thinking I would be a professional musician. I feel like I’m still mourning the loss of what my life would have been.” --Sarah Tackett, age 26